GNRH1 and Familial prostate cancer: The high anti-GnRH immune response and the drastic reduction of testosterone levels in patients with advanced prostate cancer induced by Heberprovac in the current study, has not been reported before for similar candidates in clinical trials (11–13, 18, 28).